20:07 , Jan 25, 2019 |  BC Week In Review  |  Clinical News

Cocrystal reports SVR12 rate of 67% for CC-31244 regimen

Cocrystal Pharma Inc. (NASDAQ:COCP) reported preliminary data from an open-label, U.S. Phase IIa trial showing that eight of 12 (67%) evaluable patients with treatment-naïve HCV genotype 1 infection who received 400 mg oral CC-31244 plus...
19:28 , Jun 1, 2018 |  BC Week In Review  |  Clinical News

Gilead's Epclusa approved in China for HCV

Gilead Sciences Inc. (NASDAQ:GILD) said China's State Drug Administration (formerly China FDA) approved Epclusa sofosbuvir/velpatasvir to treat adults with chronic HCV genotypes 1-6. The agency also approved Epclusa plus ribavirin to treat adults with HCV...
16:11 , May 30, 2018 |  BC Extra  |  Company News

Gilead's Epclusa approved in China for HCV

Gilead Sciences Inc. (NASDAQ:GILD) said China's State Drug Administration (formerly China FDA) approved Epclusa sofosbuvir/velpatasvir to treat adults with chronic HCV genotypes 1-6. The agency also approved Epclusa plus ribavirin to treat adults with HCV...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
01:27 , Dec 2, 2017 |  BioCentury  |  Strategy

Opening the gates in China

A flurry of approvals of HCV drugs in China this year illustrates how the country’s regulatory reforms have leveled the playing field for multinational drug sponsors, who had been disadvantaged compared with domestic companies. As...
21:54 , Sep 25, 2017 |  BC Extra  |  Company News

Gilead's Sovaldi gets Chinese approval

Gilead Sciences Inc. (NASDAQ:GILD) said China FDA approved Sovaldi sofosbuvir to treat HCV genotypes 1-6 infection as part of an antiviral treatment regimen in patients ages 12 and older. Gilead said the nucleotide analog HCV...
23:40 , Jul 7, 2017 |  BioCentury  |  Finance

Onward and upward

The top three market cap tiers continued to outperform smaller caps in 2Q17, led by companies valued between $1 billion and $9.9 billion. Companies valued below $1 billion failed to carry over their momentum from...
16:05 , May 4, 2017 |  BC Week In Review  |  Clinical News

China approves Daklinza/Sunvepra combo for HCV

Bristol-Myers Squibb Co. (NYSE:BMY) said China FDA approved Daklinza daclatasvir (BMS-790052) in combination with Sunvepra asunaprevir to treat HCV genotype 1b infection in patients with or without cirrhosis. The company said it is CFDA's first...
23:55 , Apr 28, 2017 |  BioCentury  |  Politics, Policy & Law

Access and innovation in Japan

Regulatory reforms have paved the way for innovative therapies to launch in Japan before anywhere else in the world. This should result in earlier access to more innovative medicines than ever before - but only...
22:24 , Apr 28, 2017 |  BC Extra  |  Company News

China FDA approves Daklinza combos for HCV

Bristol-Myers Squibb Co. (NYSE:BMY) said China FDA approved Daklinza daclatasvir in combination with Sunvepra asunaprevir to treat HCV genotype 1b in patients with or without cirrhosis. The company said it is CFDA's first approval of...